Agilent Technologies, Inc. $A Shares Sold by Mengis Capital Management Inc.

Mengis Capital Management Inc. lessened its stake in Agilent Technologies, Inc. (NYSE:A) by 44.9% in the 2nd quarter, Holdings Channel.com reports. The firm owned 12,414 shares of the medical research company’s stock after selling 10,100 shares during the period. Mengis Capital Management Inc.’s holdings in Agilent Technologies were worth $1,465,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in shares of Agilent Technologies by 0.7% in the first quarter. Vanguard Group Inc. now owns 33,408,626 shares of the medical research company’s stock valued at $3,908,141,000 after purchasing an additional 240,965 shares during the last quarter. Pictet Asset Management Holding SA increased its holdings in shares of Agilent Technologies by 2.5% in the first quarter. Pictet Asset Management Holding SA now owns 5,341,870 shares of the medical research company’s stock valued at $624,888,000 after purchasing an additional 128,131 shares during the last quarter. Generation Investment Management LLP increased its holdings in shares of Agilent Technologies by 19.8% in the first quarter. Generation Investment Management LLP now owns 4,983,556 shares of the medical research company’s stock valued at $582,976,000 after purchasing an additional 824,243 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Agilent Technologies by 18.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,836,105 shares of the medical research company’s stock valued at $448,748,000 after purchasing an additional 604,124 shares during the last quarter. Finally, Impax Asset Management Group plc increased its holdings in shares of Agilent Technologies by 3.6% in the first quarter. Impax Asset Management Group plc now owns 2,931,794 shares of the medical research company’s stock valued at $342,961,000 after purchasing an additional 102,365 shares during the last quarter.

Analyst Ratings Changes

A has been the subject of several recent research reports. Evercore ISI increased their price target on Agilent Technologies from $128.00 to $140.00 and gave the company an “in-line” rating in a report on Tuesday. Wells Fargo & Company increased their price objective on Agilent Technologies from $140.00 to $150.00 and gave the stock an “overweight” rating in a research report on Monday, September 15th. Wall Street Zen upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Friday, October 3rd. Barclays increased their price objective on Agilent Technologies from $125.00 to $150.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 2nd. Finally, JPMorgan Chase & Co. increased their price objective on Agilent Technologies from $155.00 to $165.00 and gave the stock an “overweight” rating in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $148.69.

Agilent Technologies Trading Down 0.5%

A opened at $140.13 on Friday. Agilent Technologies, Inc. has a 52 week low of $96.43 and a 52 week high of $153.84. The business has a fifty day simple moving average of $124.58 and a 200-day simple moving average of $116.94. The firm has a market cap of $39.73 billion, a P/E ratio of 32.89, a P/E/G ratio of 4.60 and a beta of 1.26. The company has a quick ratio of 1.71, a current ratio of 2.25 and a debt-to-equity ratio of 0.53.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, hitting the consensus estimate of $1.37. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.67 billion. During the same period last year, the business posted $1.32 earnings per share. The company’s quarterly revenue was up 10.1% on a year-over-year basis. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. On average, equities analysts expect that Agilent Technologies, Inc. will post 5.58 earnings per share for the current year.

Agilent Technologies Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 22nd. Stockholders of record on Tuesday, September 30th will be given a dividend of $0.248 per share. This represents a $0.99 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Tuesday, September 30th. Agilent Technologies’s dividend payout ratio (DPR) is currently 23.24%.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.